Capricor Therapeutics (CAPR) Accumulated Depreciation (2012 - 2026)

Capricor Therapeutics' Accumulated Depreciation history runs 12 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 53.76% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (up 53.76% YoY), while the FY2025 annual figure was $5.2 million, up 49.29% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $5.6 million, up from $5.2 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $5.6 million in Q1 2026, with the low at $830565.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation is $2.5 million (2024), against an average of $2.7 million.
• The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation grew 8.2% in 2022, then surged 86.7% in 2023.
• Capricor Therapeutics' Accumulated Depreciation stood at $1.2 million in 2022, then soared by 86.7% to $2.2 million in 2023, then surged by 56.39% to $3.5 million in 2024, then soared by 49.29% to $5.2 million in 2025, then advanced by 9.6% to $5.6 million in 2026.
• Business Quant data shows CAPR's Accumulated Depreciation at $5.6 million in Q1 2026, $5.2 million in Q4 2025, and $4.6 million in Q3 2025.